caffeic acid has been researched along with Dyslipidemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erukainure, OL; Ijomone, OM; Islam, MS; Salau, VF | 1 |
| Barre, DE; Mizier-Barre, KA | 1 |
1 review(s) available for caffeic acid and Dyslipidemias
| Article | Year |
|---|---|
The polypharmacy reduction potential of cinnamic acids and some related compounds in pre- and post-onset management of type 2 diabetes mellitus.
Topics: Acrolein; Animals; Caffeic Acids; Chlorogenic Acid; Cinnamates; Coumaric Acids; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hyperglycemia; Hypertension; Inflammation; Obesity, Abdominal; Polypharmacy | 2020 |
1 other study(ies) available for caffeic acid and Dyslipidemias
| Article | Year |
|---|---|
Caffeic acid regulates glucose homeostasis and inhibits purinergic and cholinergic activities while abating oxidative stress and dyslipidaemia in fructose-streptozotocin-induced diabetic rats.
Topics: Acetylcholinesterase; Animals; Blood Glucose; Caffeic Acids; Cholesterol; Cholinergic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Fructose; Homeostasis; Hypoglycemic Agents; Male; Oxidative Stress; Plant Extracts; Rats; Rats, Sprague-Dawley; Streptozocin | 2022 |